You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hormone Receptor Negative

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma Trial in Boston (Onvansertib, Paclitaxel)

Recruiting
  • Breast Cancer
  • +9 more
  • Boston, Massachusetts
  • +2 more
Oct 25, 2022

HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

Recruiting
  • HER2-positive Breast Cancer
  • +17 more
  • ALX148
  • Fam-Trastuzumab Deruxtecan-Nxki
  • Chicago, Illinois
  • +1 more
May 19, 2023

Breast Cancer Trial in Los Angeles, Portland (Ipilimumab, Nivolumab, Core Biopsy/Cryoablation)

Recruiting
  • Breast Cancer
  • Los Angeles, California
  • +2 more
Sep 27, 2022

Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)

Not yet recruiting
  • Advanced Solid Tumor
  • +8 more
  • (no location specified)
Nov 13, 2023

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,

Not yet recruiting
  • HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
  • PERT-IJS plus trastuzumab, carboplatin and docetaxel
  • Perjeta plus trastuzumab, carboplatin and docetaxel
  • (no location specified)
Sep 21, 2023

Breast Tumor, Breast Cancer, Breast Tumors Trial in Shanghai (Dalpiciclib, Pyrotinib, SHR-A1811)

Not yet recruiting
  • Breast Neoplasm
  • +9 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 13, 2022

Breast Cancer Trial in New Brunswick (U-13C-glucose)

Not yet recruiting
  • Breast Cancer
  • New Brunswick, New Jersey
  • +1 more
Feb 16, 2023

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial

Recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +5 more
  • Biospecimen Collection
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Dec 28, 2022

Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma Trial in Boston

Not yet recruiting
  • Male Breast Cancer
  • +2 more
  • Boston, Massachusetts
  • +1 more
Aug 12, 2022

Metastatic Breast Cancer Trial in Seoul (Fulvestrant plus AI plus ribociclib, AI plus ribociclib)

Not yet recruiting
  • Metastatic Breast Cancer
  • Fulvestrant plus AI plus ribociclib
  • AI plus ribociclib
  • Seoul, Korea, Republic of
    Korea university Guro hospital
Apr 16, 2023

Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer Trial (Ribociclib, Fulvestrant,

Not yet recruiting
  • Locoregional Recurrence
  • +2 more
  • (no location specified)
Jul 18, 2022

Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 1, 2023

    Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

    Recruiting
    • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Jun 12, 2023

    Breast Cancer Trial in Canton (TTI-101, Palbociclib, Aromatase inhibitor (AI))

    Recruiting
    • Breast Cancer
    • Saint Louis, Missouri
    • +2 more
    Jan 12, 2023

    Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers Trial (ABBV-400)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • +6 more
    • (no location specified)
    Oct 10, 2023

    Breast Tumors Trial in Guangzhou (Trilaciclib, Epirubicin, Cyclophosphamide)

    Not yet recruiting
    • Breast Neoplasms
    • Guangzhou, Gangdong, China
      Sun-yat sen university cancer center
    Jul 30, 2023

    Breast Cancer Trial in Birmingham (Letrozole, Everolimus, TRC105)

    Active, not recruiting
    • Breast Cancer
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Dec 13, 2022

    Real-World Data on First-line Treatment of Hormone

    Recruiting
    • Breast Cancer
      • Porto Alegre, Rio Grande Do Sul, Brazil
        CPO
      Aug 15, 2022

      Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Marietta, East Brunswick (Sacituzumab

      Recruiting
      • Locally Advanced or Unresectable Metastatic Breast Cancer
      • Stage IV Breast Cancer
      • Sacituzumab Govitecan-hziy
      • +3 more
      • Marietta, Georgia
      • +1 more
      Apr 21, 2023

      Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)

      Active, not recruiting
      • Metastatic Breast Cancer
      • Hospitalet de Llobregat, Barcelona, Spain
      • +6 more
      Jan 23, 2023

      Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 Trial

      Not yet recruiting
      • Anatomic Stage I Breast Cancer AJCC v8
      • +5 more
      • Atlanta, Georgia
        Emory University Hospital/Winship Cancer Institute
      Jul 14, 2022

      Invasive Breast Cancer Trial in Milwaukee (Cemiplimab, Paclitaxel, Carboplatin (not mandatory))

      Recruiting
      • Invasive Breast Cancer
      • Milwaukee, Wisconsin
        Froedtert Hospital & Medical College of Wisconsin
      Apr 1, 2022

      Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Trial in Ocala (Samuraciclib, Fulvestrant)

      Recruiting
      • Metastatic Breast Cancer
      • +2 more
      • Ocala, Florida
        Ocala Oncology Center PL DBA Florida Cancer Affiliates
      Jul 19, 2023

      Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

      Active, not recruiting
      • Hormone-receptor-positive Breast Cancer
      • +2 more
      • No drug
      • Cambridge, Massachusetts
        ConcertAI database
      Sep 8, 2023